Journals / Ege Tıp Dergisi / 2019 / Cilt: 58 - Sayı: 0

Hypersensitivity reactions to TNF-α inhibitors

TNF-Alfa Inhibitörleri Ile Tedavi Seyrinde Gelişen Alerjik Reaksiyonlar

Pages
1–5
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Intravenous or subcutaneous rapid drug desensitization is a valid therapeutic option to preclude their use in sensitized patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Patients with chronic inflammatory and autoimmune diseases are repeatedly exposed to TNF-α inhibitors.
📊
Key Findings & Data:Although these agents are generally well tolerated and safe, systemic such as urticaria, angioedema and anaphylaxis or local hypersensitivity reactions as local injection site reaction have been reported with the use of these drugs.
💡
Conclusion & Impact:Intravenous or subcutaneous rapid drug desensitization is a valid therapeutic option to preclude their use in sensitized patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Patients with chronic inflammatory and autoimmune diseases are repeatedly exposed to TNF-α inhibitors. Currently five TNF-α inhibitors such as infliximab, etanercept, adalimumab, golimumab and certolizumab are available. Although these agents are generally well tolerated and safe, systemic such as urticaria, angioedema and anaphylaxis or local hypersensitivity reactions as local injection site reaction have been reported with the use of these drugs. Intravenous or subcutaneous rapid drug desensitization is a valid therapeutic option to preclude their use in sensitized patients.

Özet

Kronik romatizmal ve alerjik hastalıkların tedavisinde TNF- α inhibitörleri sıklıkla kullanılır. Şu anda kullanımda olan beş TNF-alfa inhibitörü mevcuttur. Bunlar; infliximab, adalimumab, etanercept, golimumab, certolizumab pegol’dür. Bu ilaçlar genelde güvenlidirler ve iyi tolere edilirler ancak sistemik veya lokal enjeksiyon yeri reaksiyonu gibi aşırı duyarlık reaksiyonuna neden olabilirler. Intravenöz veya subkutan ilaç desensitizasyonu bu durumlarda etkin ve güvenli bir tedavi seçeneğidir.

🔖

Cite This Article

BAVBEK, S. (2019). Hypersensitivity reactions to TNF-α inhibitors. Ege Tıp Dergisi, Cilt: 58 - Sayı: 0, 1–5. https://ajindex.com/articles/158333

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol 2009;22(3):557-65
  2. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action:A comprehensive review. Pharmacology & Therapeutics 2008;117:244-79
  3. Corominas M, Gastaminza G, Lobera T. Hypersensitivity reactions to biological drugs. J Investig Allergol Clin Immunol 2014;24:212-25
  4. Lichtenstein L, Ron Y, Kivity S, et al. Infliximab-Related Infusion Reactions: Systematic Review. J Crohns Colitis. 2015; 9(9):806-15
  5. Murdaca G, Spanò F, Contatore M, et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin Drug Saf. 2016;15(1):43-52
  6. Culy CR, Keating GM. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 2002;62:2493-537
  7. Fleischmann R, Baumgartner SW, Weisman MH, et al. Long term safety of etancercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006;65:379-84
  8. Benucci M, Manfredi M, Demoly P, et al. Injection site reactions to TNF-α blocking agents with positive skin tests. Allergy 2008;63:138-9
  9. Paltiel M, Gober LM, Deng A, et al. Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab. Arch Dermatol 2008;144(9):1190-4
  10. Sator P. Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience. Ther Adv Chronic Dis 2018;9(8):147-58
  11. Santos RB, Galvão VR. Monoclonal Antibodies Hypersensitivity: Prevalence and Management. Immunol Allergy Clin North Am 2017;37(4):695-711
  12. Ma X, Xu S. TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep. 2013 Mar;1(2):177-84
  13. Launois R, Avouac B, Berenbaum F, et al. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. J Rheumatol 2011;38(5):835-45
  14. Patel SV, Khan DA. Adverse Reactions to Biologic Therapy. Immunol Allergy Clin North Am 2017 May;37(2):397-412
  15. Borra´s-Blasco J, Navarro-Ruiz A, Borra´s C, et al. Adverse Cutaneous Reactions Induced by TNF-α Antagonist Therapy.Southern Med J 2009;102 (11): 1133-9
  16. Wendling D, Verhoeven F, Guillot X, Prati C. Immu